Viewing Study NCT03737851


Ignite Creation Date: 2025-12-24 @ 11:51 PM
Ignite Modification Date: 2026-02-25 @ 5:54 PM
Study NCT ID: NCT03737851
Status: COMPLETED
Last Update Posted: 2023-12-22
First Post: 2018-11-06
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Sponsor: AbbVie
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Sclerosis (MS) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Relapsing multiple sclerosis View
None Multiple sclerosis View
None Elezanumab View
None ABT-555 View